Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
Rhea-AI Summary
Dermata Therapeutics (NASDAQ:DRMA) reported second quarter 2026 results and detailed its pivot to a commercial-stage, direct-to-consumer skincare model centered on its new Tome brand. The company expects to launch its first product, Tome Foundational Treatment, on August 25, 2026, with manufacturing and packaging completed and a social media campaign underway.
As of June 30, 2026, Dermata held $4.4 million in cash and cash equivalents versus $7.5 million at year-end 2025, and expects this to fund operations into Q4 2026. Q2 2026 research and development expenses declined to $0.2 million, while selling, general and administrative expenses rose to $2.8 million driven by higher legal, marketing, commercialization, and reallocated employee costs. Total assets were $5.3 million, equity was $3.5 million, and the company reported a Q2 2026 net loss of $3.0 million, or $(0.74) per share.
Positive
- First product launch set for August 25, 2026, with manufacturing and packaging completed for Tome Foundational Treatment
- Cash runway expected to fund operations into the fourth quarter of 2026 based on current resources
- Research and development expenses down to $0.2 million in Q2 2026 from $0.6 million in Q2 2025
- ATM financing proceeds of approximately $1.9 million in the first half of 2026
- Growing share base with 4.0 million weighted average common shares outstanding in Q2 2026 versus 1.0 million in Q2 2025
Negative
- Net loss widened to $3.0 million in Q2 2026 from $1.7 million in Q2 2025
- Cash and cash equivalents decreased to $4.4 million from $7.5 million over six months
- Selling, general and administrative expenses more than doubled to $2.8 million in Q2 2026 from $1.2 million in Q2 2025
- Equity declined to $3.5 million at June 30, 2026 from $6.2 million at December 31, 2025
- Operating cash used of $4.9 million for the six months ended June 30, 2026
News Explained
The company has cash from an approximately $1.9 million ATM financing, but its effect on existing ownership is undisclosed as the first product remains pre-launch.
The company reported that manufacturing and packaging for Tome Foundational Treatment were finished and that its first direct-to-consumer launch is expected on
Thus, the product is prepared but not yet reported as launched, while the release reports approximately
The release does not provide the ATM issuance's security count, price, dilution, conversion terms, or use of proceeds, so the financing's effect on existing ownership cannot be established from this disclosure.
The six-month cash bridge reports
The next stated checkpoint is
Market Reaction – DRMA
Following this news, DRMA has gained 42.59%, reflecting a significant positive market reaction. Argus tracked a peak move of +50.7% during the session. Our momentum scanner has triggered 71 alerts so far, indicating high trading interest and price volatility. The stock is currently trading at $1.54. Trading volume is exceptionally heavy at 232.8x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | 1Q26 earnings report | Positive | +3.4% | DTC pivot, ATM proceeds, cash position, and planned Tome launch |
| Mar 26 | FY25 earnings report | Negative | -13.9% | Strategic pivot, financing history, cash runway, and discontinued prescription program |
| Nov 14 | 3Q25 earnings report | Positive | -7.5% | Positive Phase 3 results, OTC strategy, and cash runway |
| Aug 13 | 2Q25 earnings report | Positive | -9.8% | Positive Phase 3 results, financing, cash balance, and expense changes |
| May 14 | 1Q25 earnings report | Positive | -0.1% | Positive Phase 3 results, collaboration agreement, financing, and cash runway |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Across five earnings-tagged events, the average reported 24-hour reaction was -5.58%, with negative reactions following four listed events.
Key Terms
direct-to-consumer financial
over-the-counter (otc) regulatory
atm financing financial
stock-based compensation financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026 -
- Dermata recently attended Be+Well Beauty and Wellness Show in Las Vegas, NV to announce the Tome brand -
SAN DIEGO, CA / ACCESS Newswire / August 11, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the second quarter ended June 30, 2026.
"Over the past year, we have transformed Dermata through a strategic pivot to become a commercial-stage, direct-to-consumer skincare company," commented Gerry Proehl, Dermata's Chairman, President, and CEO. "This transition has been marked by significant execution across our organization, culminating in the development of our first commercial product, Tome Foundational Treatment, which we expect to start selling on August 25, 2026. As we prepare to enter the consumer skincare market, we believe we've identified the untapped 'white space' to launch our inaugural Tome product. We expect this launch will allow Dermata to begin generating revenues in the near future while continuing to build long-term value for our shareholders," continued Mr. Proehl. "Looking ahead, we believe the opportunities before us extend well beyond the launch of a single product. Our direct-to-consumer platform provides the foundation to build lasting relationships with consumers, leverage data-driven insights to optimize marketing and customer engagement, and efficiently expand our product portfolio over time. We are excited to execute on our commercial strategy, establish a differentiated skincare brand, and create a scalable business that we believe can drive sustainable growth and enhance shareholder value for years to come," concluded Mr. Proehl.
Corporate Highlights
Attended first trade show, Be+Well Beauty and Wellness Show in Las Vegas announcing its Tome brand. In June 2026, the Dermata team exhibited at the Be+Well Beauty and Wellness Show to officially launch the Tome brand and provided attendees with more information on the upcoming launch of its Foundational Treatment. The Be+Well conference hosts thousands of esthetics, spa, and wellness professionals with over 400+ brands in attendance.
Began social media campaign for its new skincare brand, Tome. The Company recently unveiled the Tome brand's official social media presence as part of the Company's broader commercial launch strategy. These efforts are designed to increase brand awareness, engage prospective consumers, and support the successful ecommerce launch of the Company's first commercial skincare product, Tome Foundational Treatment, expected on August 25, 2026.
Anticipated Upcoming Milestones
Launch first direct-to-consumer (DTC) skincare product, Tome Foundational Treatment, expected on August 25, 2026. The Company has finished manufacturing and packaging for its Tome Foundational Treatment and is prepared for the upcoming commercial launch. The Company believes the Tome Foundational Treatment can be the base of any skincare routine, designed to renew the appearance of the skin and simplify skincare with a once-weekly application.
Continue development of a second DTC product. The Company is also working on its second skincare product, a once weekly, over-the-counter (OTC) topical treatment for acne, which is expected to launch sometime after its Foundational Treatment.
Second Quarter 2026 Financial Results
As of June 30, 2026, the Company had
Research and development expenses were
Selling, general and administrative expenses were
About Dermata Therapeutics
Dermata Therapeutics is a scientific leader in dermatologic solutions that recently announced a strategic pivot from pharmaceutical development to begin focusing on the development and commercialization of direct-to-consumer skincare solutions. The Company is currently developing a first-of-its-kind skin renewal treatment which incorporates Dermata's Bioneedle™. The Company expects to launch its first product on August 25, 2026, with additional innovations planned to follow. Dermata is headquartered in San Diego, California. For more information, or to join our mailing list, please visit http://www.dermatarx.com/.
About Tome
Tome is Dermata's new skincare line focused on bringing about a new realm of skincare that is powerful, not punishing. Tome in its literal meaning is a large, important, scholarly book. Dermata intends to educate consumers with a brand that tells a skincare story rooted in science and history. Tome will consist of a line of skincare products incorporating its Bioneedle, utilizing Spongilla lacustris, a wild harvested, freshwater sponge that has evolved over millions of years, as the primary ingredient for consumers that are compelled by history and science to find the most potent products for their skincare routine. Dermata believes its Tome skincare line will simplify existing skincare routines with essential ingredients that deliver results, without the recovery associated with in-office treatments. Dermata expects to launch its first product, Tome Foundational Treatment, on August 25, 2026, with additional product launches planned to follow. Start your skincare story at www.tomeskincare.com.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: Dermata's shift to prioritize DTC and OTC skincare products; the anticipated benefits of Dermata's strategic shift to prioritize DTC and OTC skincare products, including acceleration of its path to commercialization, reduction of regulatory burdens, and expansion into broader consumer markets; the success, cost, and timing of the launch of its planned or future DTC and OTC products, including the Tome Foundational Treatment; the expected timing and success of any planned or future DTC and OTC product launches; expectations for the success of the Company's products and their ability to generate revenue for the Company; the Company's expectations with regard to current cash and cash equivalents and the amount of time it will fund operations; and other factors described in the Company's filings with the Securities and Exchange Commission. These forward-looking statements are generally identified by the use of such words as "may," "could," "should," "would," "believe," "anticipate," "forecast," "estimate," "expect," "intend," "plan," "continue," "outlook," "will," "potential" and similar statements of a future or forward-looking nature. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in product development and commercialization. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
DERMATA THERAPEUTICS, INC.
Balance Sheets
In thousands USD | June 30, 2026 | December 31, 2025 | ||||||
(unaudited) | ||||||||
Assets |
| |||||||
Cash and cash equivalents | $ | 4,413 | $ | 7,522 | ||||
Prepaid expenses and other current assets | 594 | 342 | ||||||
Inventories | 150 | - | ||||||
Non-current assets | 164 | - | ||||||
Total assets | 5,321 | 7,864 | ||||||
Liabilities | ||||||||
Accounts payable | 1,120 | 461 | ||||||
Accrued liabilities | 713 | 1,180 | ||||||
Total liabilities | 1,833 | 1,641 | ||||||
Equity | 3,488 | 6,223 | ||||||
Total liabilities and equity | $ | 5,321 | $ | 7,864 | ||||
DERMATA THERAPEUTICS, INC.
Statements of Operations
(unaudited)
Quarter Ended June 30, | Six Months Ended June 30, | |||||||||||||||
In thousands, except share and per share data | 2026 | 2025 | 2026 | 2025 | ||||||||||||
|
|
|
| |||||||||||||
Operating expenses |
|
|
|
| ||||||||||||
Research and development (1) | $ | 213 | $ | 618 | $ | 596 | $ | 1,899 | ||||||||
Selling, general and administrative (1) | 2,801 | 1,155 | 4,344 | 2,214 | ||||||||||||
Total operating expenses | 3,014 | 1,773 | 4,940 | 4,113 | ||||||||||||
Loss from operations | (3,014 | ) | (1,773 | ) | (4,940 | ) | (4,113 | ) | ||||||||
Interest income | 47 | 72 | 125 | 108 | ||||||||||||
Net loss | $ | (2,967 | ) | $ | (1,701 | ) | $ | (4,815 | ) | $ | (4,005 | ) | ||||
Net loss per common share, basic and diluted | $ | (0.74 | ) | $ | (1.66 | ) | $ | (1.22 | ) | $ | (5.18 | ) | ||||
Weighted average common shares outstanding, basic and diluted | 4,022,143 | 1,026,506 | 3,940,983 | 772,397 | ||||||||||||
(1) Includes the following stock-based compensation expense | ||||||||||||||||
Research and development | $ | 4 | $ | 8 | $ | 18 | $ | 16 | ||||||||
Selling, general and administrative | $ | 38 | $ | 31 | $ | 67 | $ | 61 | ||||||||
Investor Contact:
Cliff Mastricola
Investor Relations
cmastricola@dermatarx.com
SOURCE: Dermata Therapeutics
View the original press release on ACCESS Newswire